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Abstract
The cytoplasmic tyrosine kinase Jak2 plays a crucial role in cytokine receptor signaling in hematopoietic cells. The activated
Jak2-V617F mutant is present in most cases of BCR/ABL-negative myeloproliferative neoplasms and constitutively activates
downstream signals from homodimeric cytokine receptors, such as the erythropoietin receptor (EpoR). Here we examine the
effects of DNA damage stress on Jak2 or Jak2-V617F and on induction of apoptosis in hematopoietic cells. Etoposide or
doxorubicin dose-dependently decreased the expression level of Jak2 in UT7 or 32D cells expressing EpoR in the absence of
Epo and that of exogenously expressed Jak2-V617F in UT7 cells when cotreated with the Jak2 inhibitor JakI-1 or AG490.
Studies with pharmacological inhibitors and genetic manipulations further showed that downregulation of the PI3K/Akt
pathway leading to the activation of GSK3b may be involved in downregulation of Jak2 or Jak2-V617F as well as in
synergistic induction of Bax activation and apoptosis. The downregulation of Jak2 was inhibited by the proteasome
inhibitor MG132 or by expression of both of loss-of-function mutants of c-Cbl and Cbl-b, E3 ubiquitin ligases which
facilitated ubiquitination of Jak2-V617F when co-expressed in 293T cells. The pan-caspase inhibitor Boc-d-fmk also inhibited
the Jak2 downregulation as well as appearance of a 100-kDa fragment that contained the N-terminal portion of Jak2 in
response to DNA damage. Together, these data suggest that DNA damage stress with simultaneous inhibition of the kinase
activity causes degradation of Jak2 or Jak2-V617F by caspase cleavage and proteasomal degradation through GSK3b
activation, which is closely involved in synergistic induction of apoptosis in hematopoietic cells.
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Introduction
The cytoplasmic tyrosine kinase Jak2 couples with a variety of
cytokine receptors, such as the erythropoietin (Epo) receptor
(EpoR) and the IL-3 receptor, and plays a crucial role in regulation
of proliferation and apoptosis of hematopoietic cells by activating
various signaling pathways including the STAT5, RAS/Raf-1/
MEK/Erk, and phosphatidylinositol 3’-kinase (PI3K)/Akt path-
ways [1,2]. The serine/threonine kinase glycogen synthase kinase-
3b (GSK3b) is constitutively active in cells and is regulated
through inhibitory phosphorylation on S9 mainly by Akt [3].
GSK3b plays an important role in regulation of protein stability
and is involved in regulation of a wide range of cellular processes,
ranging from glycogen metabolism to cell-cycle regulation and
apoptosis [3,4,5]. We have previously shown that a Jak2 inhibitor,
Jak inhibitor-I (JakI-1) [6], activated GSK3b by inactivating the
PI3K/Akt pathway to phosphorylate cyclin D2 on T280, which
triggered its degradation through the ubiquitin proteasome
pathway leading to cell cycle arrest of Epo- or IL-3-dependent
hematopoietic cells [7]. The somatic valine-to-phenylalanine
mutation in the pseudokinase domain of Jak2 (Jak2-V617F) has
been found in the majority of patients with polycythemia vera and
in about 50% of patients with the other myeloproliferative
neoplasms, essential thrombocythemia and primary myelofibrosis
[1,8]. Jak2-V617F is constitutively activated without cytokine
stimulation and when coexpressed with homodimeric cytokine
receptors, such as EpoR, activates the various downstream
pathways leading to cytokine-independent hematopoietic cell
proliferation.
Chemotherapeutic agents, including the topoisomerase II
inhibitor etoposide and the anthracycline doxorubicin, mostly
damage DNA and activate the intrinsic apoptotic pathway leading
from Bax activation to mitochondrial damage and caspase
activation [9]. We previously found that Epo or IL-3 significantly
inhibited etoposide-induced apoptosis in hematopoietic cells
mainly through activation of the PI3K/Akt pathway [10]. The
inhibition of GSK3b was shown to be required for etoposide to
activate the Chk1 kinase to induce G2/M cell cycle arrest and to
attenuate apoptosis. However, it has remained to be examined
whether other mechanisms may also be involved in synergistic
induction of apoptosis by DNA damage stress and inhibition of
Jak2 signaling. It is speculated that Jak2-V617F may also confer
resistance to chemotherapeutic agents on hematopoietic cells
through the identical mechanisms, which may be abrogated by
inhibiting the aberrant kinase activity. Because several Jak2
inhibitors have been developed and under clinical evaluation as
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limited success [11], the combined effects of Jak2 inhibitors and
DNA-damaging chemotherapeutic agents and the mechanisms
involved in possible synergy are warranted to be studied in detail
to develop effective therapeutic strategies for these diseases.
In the present study, we examine the possible effect of DNA
damage stress on Jak2 and Jak2-V617F signaling in hematopoietic
cells. We find that when the PI3K/Akt pathway is inhibited,
GSK3b is activated by DNA damage stress and plays a role in
downregulation of Jak2 and Jak2-V617F and in synergistic
induction of apoptosis. Furthermore, we show that the downreg-
ulation of Jak2 and Jak2-V617F is mediated by cleavage by
caspases as well as through the ubiquitin proteasome system
involving the E3 ubiquitin ligases c-Cbl and Cbl-b.
Results
Etoposide as well as doxorubicin downregulates Jak2
and Jak2-V617F when they are inactivated
To study the possible effect of DNA damage stress on Jak2
stability, a human leukemic cell line, UT7 [12], which expresses
the wild-type Jak2 and endogenous EpoR, was treated with
etoposide or doxorubicin and examined by immunoblot analysis.
As shown in Fig. 1A, etoposide or doxorubicin nearly eliminated
the expression level of Jak2 as well as EpoR in the absence of Epo,
but not in its presence. We next examined the effects of various
concentrations of etoposide as well as doxorubicin on Jak2 in a
murine hematopoietic cells line, 32D/EpoR, which also expresses
wild-type Jak2 and heterologously expressed EpoR [13]. As shown
in Fig. 1B and 1C, etoposide as well as doxorubicin dose-
dependently decreased the expression of Jak2 only when cells were
starved of Epo. It was also observed that p53, a major player in
DNA-damage signaling, was significantly induced by etoposide or
doxorubicin only in the presence of Epo. To address the possibility
that EpoR may influence the effect of DNA damage stress on Jak2,
we then examined the effects of etoposide on Jak2 comparatively
in 32D/EpoR and in the parental IL-3-dependent 32Dcl3 cells. As
shown in Fig. 1D, when these cells were cultured with and
subsequently deprived of IL-3, etoposide significantly decreased
the Jak2 expression in 32D/EpoR but not in 32Dcl3 cells, thus
suggesting that the presence of EpoR may facilitate the decline in
Jak2 expression. Next, we examined UT7 cells expressing the
constitutively activated Jak2-V617F mutant. Even in the absence
of Epo, neither etoposide nor doxorubicin significantly downreg-
ulated Jak2 in UT7/Jak2-V617F cells unlike in parental UT7 cells
(Fig. 1A, 1E and 1F). However, when the kinase activity was
inhibited by the Jak2 inhibitor JakI-1, etoposide as well as
doxorubicin dose-dependently decreased the Jak2 expression in
UT7/Jak2-V617F. It was also observed that the Jak2 inhibitor
AG490 dose-dependently suppressed the Jak2 expression in UT7/
Jak2-V617F treated with etoposide or doxorubicin (Fig. 1G).
Together, these data suggest that DNA damage stress may induce
a decline in expression level of Jak2 or Jak2-V617F selectively in
cells in which the kinase is in inactive state and preferentially in
cells that express EpoR.
Involvement of the PI3K/Akt/GSK3b pathway in
downregulation of Jak2 in response to DNA damage
To elucidate the mechanisms by which DNA damage stress
selectively decreases the expression level of inactive Jak2, we next
examined the possible involvement of signaling pathways down-
stream of Jak2. As shown in Fig. 2A, the PI3K inhibitor
LY294002, but not the MEK inhibitor PD98059, significantly
accelerated the etoposide-induced downregulation of Jak2 in UT7
cells cultured with Epo. It was also noted that treatment of cells
with etoposide or doxorubicin significantly reduced the inhibitory
phosphorylation of GSK3b, a target of Akt activated downstream
of PI3K, particularly in the absence of Epo (Fig. 2A). These
observations raise a possibility that activation of the PI3K pathway
leading to Akt-mediated inactivation of GSK3b may confer the
resistance on Jak2. To examine this possibility, we next
comparatively examined 32D/Akt-myr cells, which express the
constitutively activated Akt mutant, and the vector-control 32D/
RevTRE cells. Because these cells do not express EpoR and, thus,
are resistant to DNA damage stress-induced decline in Jak2
expression, we pretreated these cells with JakI-1 or with LY294002
before treating with etoposide in the absence of IL-3. As shown in
Fig. 2B, pretreatment with these inhibitors allowed etoposide to
decrease the Jak2 expression more significantly in control cells
than in cells expressing Akt-myr, thus supporting the idea that Akt
activated downstream of PI3K may confer the resistance on Jak2.
We next examined the involvement of GSK3b by using its
inhibitors, LiCl and SB216763, and found that these inhibitors
prevented the decrease in Jak2 expression in UT7 cells treated
with etoposide in the absence of Epo (Fig. 2C). Intriguingly, the
PP2A inhibitor okadaic acid, previously reported to inactivate
GSK3b [14], also prevented the decrease in both Jak2 and the
inhibitory phosphorylation of GSK3b in a dose-dependent
manner.
We also examined the possible involvement of STAT5
activation, one of the most critical Jak2 downstream signaling
events, in Jak2 downregulation under DNA damage stress. For this
purpose, we expressed a constitutively activated STAT5 mutant,
STAT5A1*6 [15], in 32D/EpoR and examined the response to
etoposide. As shown in Fig. 2D, etoposide treatment in the
absence of Epo downregulated Jak2 expression in vector-control
cells but not in cells expressing STAT5A1*6, which expressed Jak2
at a higher level than that in control cells. Intriguingly, the
inhibitory phosphorylation of GSK3b was enhanced and was not
inhibited by etoposide in cells expressing STAT5A1*6. However,
Jak2 was downregulated when cells were treated with etoposide in
the presence of LY294002 or, to a lesser extent, JakI-1, which also
inhibited the inhibitory phosphorylation of GSK3b. To address
the possible mechanisms involved in inhibition of GSK3b by
STAT5A1*6, we immunoprecipitated and examined the regula-
tory p85 component of PI3K. Fig. 2E demonstrates that STAT5
as well as various tyrosine phosphorylated proteins are physically
associated with p85 in cells expressing STAT5A1*6 but not in
control cells. This is in accordance with a previous report that the
PI3K/Akt pathway is activated by STAT5A1*6 through forma-
tion of molecular complexes containing p85 and STAT5 [16].
Thus, these data suggest that STAT5A1*6, or possibly activated
endogenous STAT5, may inhibit GSK3b through the PI3K/Akt
pathway to prevent the Jak2 downregulation under DNA damage
stress.
We next examined whether Jak2-V617F is regulated similarly
with wild-type Jak2 under DNA damage stress. As shown in
Fig. 2F, pretreatment of UT7/Jak2-V617F cells with LY294002 as
well as JakI-1 allowed etoposide to decrease the expression level of
Jak2, which was prevented by co-treatment with LiCl, thus
suggesting that Jak2-V617F as well as cytokine-stimulated Jak2
prevents its downregulation under DNA damage stress by
activating the PI3K/Akt pathway to inhibit GSK3b activation.
Possible involvement of ubiquitin-proteasome pathway
and Cbls in downregulation of Jak2
To address the possibility that Jak2 may undergo degradation in
cells under DNA damage stress, we pretreated 32D/EpoR cells
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etoposide. As shown in Fig. 3A, the decrease in Jak2 expression in
these cells was prevented by MG132, which also prevented the
decline in Jak2-V617 in cells treated with both LY294002 and
etoposide (Fig. 2F). These data suggest that Jak2 as well as Jak2-
V617F may be degraded at least partly through the proteasome
pathway in response to DNA damage stress unless GSK3b is
inactivated downstream of the PI3K/Akt pathway.
Because ubiquitination plays a critical role in regulation of
proteasomal degradation of various proteins including tyrosine
kinases [17], we studied ubiquitination of Jak2 transiently
expressed with ubiquitin in 293T cells. As shown in Fig. 3B,
wild-type Jak2 but not a kinase-dead Jak2 mutant was significantly
polyubiquitinated when co-expressed with EpoR. In accordance
with our previous report, Jak2 becomes activated and autopho-
sphorylated on Y1007 in the activation loop without Epo
stimulation when overexpressed with EpoR [18]. Thus, these
data are also in accordance with a previous report that the
phosphorylation on Y1007 is critical for polyubiquitination of Jak2
[19]. On the other hand, Jak2-V617F was constitutively
phosphorylated on Y1007 without EpoR and was ubiquitinated
when coexpressed with ubiquitin in 293T cells, which was detected
by immunoblotting with anti-phospho-Y1007-Jak2 antibody as
additional slowly migrating bands and the typical smeary pattern
(Fig. 3C). Intriguingly, ubiquitination of Jak2-V617F was signif-
icantly enhanced by co-expressing c-Cbl or Cbl-b, the E3
ubiquitin ligase known to play important roles in regulation of
degradation of various tyrosine kinases through the ubiquitin
proteasome pathway as well as in leukemogenesis [20,21].
To address the possibility that the Cbl ubiquitin ligases may be
involved in degradation of Jak2 under DNA damage stress, we
next examined 32D cells that overexpress both c-Cbl-R420Q and
Cbl-b-C373A, loss-of-function mutants of the ubiquitin ligases. As
shown in Fig. 3D, the decline in Jak2 expression induced by
treatment with etoposide or doxorubicin in the presence of
LY294002 was significantly attenuated by overexpression of these
putative dominant negative mutants. These data strongly implicate
c-Cbl as well as Cbl-b in regulation of Jak2 degradation under
DNA damage stress.
Caspase activation is involved in Jak2 degradation in cells
under DNA damage stress
We have previously shown that inhibition of the PI3K pathway
by LY294002 or by cytokine deprivation synergistically enhanced
etoposide-induced apoptosis of hematopoietic cells, including 32D
and UT7, at least partly by inhibiting the Chk1-mediated G2/M
checkpoint activation [10]. To examine whether similar synergistic
effects could be observed in UT7 cells expressing Jak2-V617F, we
treated these cells with etoposide and JakI-1 or LY294002.
Treatment of UT7/Jak2-V617F cells with etoposide alone for 12 h
induced G2/M arrest without significantly inducing apoptosis.
However, cotreatment with JakI-1 or LY294002 synergistically
enhanced etoposide-induced apoptosis as detected by cells with
sub-G1 DNA content, which was prevented by inhibiting GSK3b
by adding the specific inhibitor GSK3I-5 or LiCl (Fig. 4A and data
not shown). Thus, apoptosis induced by etoposide in combination
with these inhibitors correlated with the decline in Jak2-V617F
expression, which raises the possibility that activation of caspases
may be involved in degradation of Jak2-V617F as well as Jak2.
To address this possibility, we utilized the pan-caspase inhibitor
Boc-d-fmk, which effectively prevented apoptosis induced by
combined treatment of UT7/Jak2-V617F cells with etoposide and
Figure 1. Etoposide as well as doxorubicin downregulates Jak2 and Jak2-V617F when they are inactivated. (A) After cultured for 9 h in
medium without Epo, UT7 cells were left untreated or treated with 5 mM etoposide (VP16) or 0.5 mM doxorubicin (DXR) for 4 hr in the absence or
presence of 50 mU/ml Epo, as indicated. Cells were lysed and subjected to immunoblot analysis with anti-Jak2 antibody, followed by reprobing with
anti-EpoR and anti-b-actin, as indicated. (B, C) After cultured for 3 h in medium without Epo, 32D/EpoR cells were treated for 5 h in the absence or
presence of 100 mU/ml Epo, as indicated, with increasing concentrations of etoposide (C) or doxorubicin (D), as indicated. Cell lysates were analyzed
by immunoblotting with antibodies against indicated proteins. (D) 32D/EpoR or parental 32Dcl3 cells, cultured in medium containing 10% WEHI
conditioning medium as the source of IL-3, were washed out of cytokine for 1 h. Cells were further cultured with or without 5 mM etoposide (VP16)
for 6 h, as indicated, and analyzed. (E, F) After cultured for 9 h in medium without Epo, UT7/Jak2-V617F cells were treated for 1 h with or without
2 mM JakI-1. Cells were subsequently treated with increasing concentrations of etoposide (E; 0, 1, 2, 5 mM) or doxorubicin (D; 0, 0.1, 0.2, 0.5 mM), as
indicated, and analyzed. (G) UT7/Jak2-V617F cells starved from Epo were pretreated with indicated concentrations of AG490 for 1 h. Cells were then
treated with 5 mM etoposide or 0.5 mM doxorubicin for 6 h, as indicated, and analyzed.
doi:10.1371/journal.pone.0027397.g001
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protected Jak2 from degradation in 32D/EpoR cells treated with
etoposide or doxorubicin in the absence of Epo. Similarly, Boc-d-
fmk protected degradation of Jak2-V617F in UT7/Jak2-V617F
cells treated with both JakI-1 and etoposide (Fig. 4E).
To confirm the relevant caspase activation in these cells, we
next examined by flow-cytometry the expression level in UT7/
Jak2-V617F cells of cleaved and, thus, activated caspase-3 as well
as that of Bax in activated conformation, which acts upstream of
mitochondria to initiate the intrinsic apoptotic signaling
pathways leading to activation of the executioner caspase,
caspase-3 [9]. As shown in Fig. 5A, treatment with etoposide
or JakI-1 alone for 6 h or 7 h, respectively, only marginally
activated Bax and caspase-3. However, in the presence of JakI-1,
etoposide began to activate Bax and caspase-3 as early as 3 h
after treatment and significantly activated these molecules after
6 h of treatment. These data indicate that etoposide and JakI-1
synergistically and rapidly activate the Bax-mediated apoptotic
pathway leading to the cleavage of caspase-3. Thus, the
activation of caspase-3 and the degradation of Jak2-V617F
correlated in UT7 cells treated with JakI-1 and etoposide. We
next examined the effects of Boc-d-fmk and GSK3I-5 on
apoptosis-inducing events in these cells. As expected, JakI-1
drastically enhanced etoposide-induced decline of mitochondrial
membrane potential, the downstream event of Bax activation,
which leads to the activation of caspase cascade (Fig. 5B). Boc-d-
fmk partially inhibited the cleavage of caspase-3 without showing
any inhibitory effects on activation of Bax and decline of
mitochondrial membrane potential, which is in agreement with
the idea that the latter events are upstream of the former.
Intriguingly, the GSK3b inhibitor remarkably inhibited activa-
tion of Bax as well as decline of mitochondrial membrane
potential, thus significantly reducing the caspase-3 activation.
Therefore, the effects of these inhibitors on caspase-3 activation
correlated with those on Jak2-V617F degradation. These data
also indicate that activation of GSK3b m a yp l a yac r i t i c a lr o l ei n
synergistic activation of Bax by the combined treatment with
JakI-1 and etoposide.
Figure 2. Involvement of the PI3K/Akt/GSK3b pathway in downregulation of Jak2 in response to DNA damage. (A) After cultured for
9 h in medium without Epo, UT7 cells were pretreated for 1 h with 50 mM LY294002 (PI3K-I) or 50 mM PD98059 (MEK-I), as indicated, or left untreated.
Cells were subsequently treated with or without 10 mM etoposide (VP16) for 4 h, as indicated, in the presence of 20 mU/ml Epo or in its absence (Epo
-). Cells were lysed and subjected to immunoblot analysis with anti-Jak2 antibody, followed by sequential reprobing with anti-phospho-GSK3a/b-S9/
21 (GSK3b-P), anti-GSK3b, anti-b-actin, as indicated. (B) 32D/Akt-myr (Akt-myr) as well as control 32D/RevTRE (Cont.) cells were cultured for 24 h with
1 mg/ml doxycycline to induced the expression of Akt-myr in 32D/Akt-myr cells and subsequently washed out of WEHI conditioning medium for 12 h.
Cells were then pretreated for 1 h with 1 mM JakI-1 or 10 mM LY294002 (PI3K-I), as indicated, or left untreated. Cells were finally treated with or
without 10 mM etoposide (VP16), as indicated, for 4 h before analysis with indicated antibodies. (C) After cultured for 9 h in medium without Epo, UT7
cells were pretreated for 1 h with 10 mM SB216763 (SB216), 40 mM LiCl, or okadaic acid at 100 nM (OA100) or 200 nM (OA200), as indicated, or left
untreated. Cells were subsequently treated with or without 10 mM etoposide (VP16) for 4 h, as indicated, and analyzed. (D) 32DE/STAT5A1*6
(STAT5A1*6) or control 32DE/pMX (Cont.) cells were pretreated for 1 h with 1 mM JakI-1 or 50 mM LY294002 (PI3K-I), as indicated, or left untreated in
the absence of Epo. Cells were further treated with or without 5 mM etoposide (VP16) for 6 h, as indicated, before analysis. (E) 32DE/STAT5A1*6
(STAT5A1*6) or control 32DE/pMX (Cont.) cells were cultured overnight in the absence of Epo. Cells were lysed and subjected to immunoprecipitation
of p85. Immunoprecipitates were analyzed by immunoblotting. (F) After cultured for 12 h in medium without Epo, UT7/Jak2-V617F cells were
pretreated for 1 h with 50 mM LY294002 (PI3K-I), 2 mM JakI-1, 40 mM LiCl, or 10 mM MG132, as indicated, or left untreated as control (Cont.). Cells
were subsequently treated with or without 5 mM etoposide (VP16), as indicated, for 6 h and analyzed.
doi:10.1371/journal.pone.0027397.g002
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be detected after caspase activation in cells under DNA damage
stress. 32D/EpoR cells deprived of Epo were treated with
etoposide, and Jak2 was immunoprecipitated with an antibody
against the Jak2 amino acids 758–776, anti-Jak2 (06–255), and
immunoblotted with an antibody against Jak2 amino acids 190–
315, anti-Jak2 (M-126). Although a band of about 95 kDa was
constantly observed in addition to the 130-kDa band correspond-
ing to full-length Jak2 in all the samples, a band of about 100 kDa
was conspicuously observed only in a sample from cells treated
with etoposide but not from cells left untreated or treated with
both etoposide and Boc-d-fmk (Fig. 5C). These additional bands
were not observed when an antibody against the C-terminal
polypeptide of Jak2, anti-Jak2 (C-20), was used for immunodetec-
tion. This antibody also failed to detect the expected smaller C-
terminal fragment of Jak2. Similarly, treatment of UT7/Jak2-
V617F cells with both JakI-1 and etoposide produced an extra
band of about 100 kDa that was immunoprecipitated with anti-
Jak2 (06–255) and detected by anti-Jak2 (M-126) but not by anti-
Jak2 (C-20). This band was also detected by antibody against the
Flag epitope, which was tagged at the N-terminus of Jak2-V617F.
Conversely, cell lysates were subjected to immunoprecipitation
with anti-Flag and probed with anti-Jak2 (16–255). As expected,
the 100-kDa band was detected only when cells were treated with
both etoposide and JakI-1 but not when they were similarly treated
in the presence of Boc-d-fmk or left untreated (Fig. 5E). These data
Figure 3. Possible involvement of ubiquitin-proteasome pathway and Cbls in downregulation of Jak2. (A) 32D/EpoR cells deprived of
Epo for 2 h were pretreated with 10 mM MG132 or left untreated as control, as indicated for 1 h in the absence of Epo. Cells were then treated for 6 h
with or without 5 mM etoposide, as indicated. Cells were lysed and subjected to immunoblot analysis using indicated antibodies. (B) 293T cells were
transfected on 6-well plate with 0.1 mg of pRK5-Ubiquitin-WT and 0.002 mg of pRK5-Jak2-Wt (Wt) or pRK5-Jak2-KE (KE) along with 0.1 mg of pXM-
EpoR-Wt or empty plasmid, as indicated. Two days after transfection, cells were lysed, and Jak2 was immunoprecipitated. Immunoprecipitates were
analyzed by immunoblotting using antibodies against polyubiquitin (poly-Ubi), Jak2, and Jak2 phosphorylated on Y1007 (Jak2-PY), as indicated. The
vertical line indicates the smeary pattern characteristic of ubiquitination. (C) 293T cells were transfected on 6-well plate with 0.3 mg of pRevTRE-
Jak2V617F and 0.2 mg of pTet-On along with 0.2 mg of pRK5-Ubiquitin-WT (Ubi), 0.5 mg of pRevTRE-c-Cbl (c-Cbl), or 0.5 mg of pRevTRE-Cbl-b (Cbl-b),
as indicated. The amounts of plasmid DNA transfected were equalized by adding pRevTRE. Two days after transfection, cells were lysed, and lysates
were analyzed by immunoblotting. The position of unmodified Jak2-V617F and those of ubiquitinated Jak2-V617F are indicated by asterisks and
arrows, respectively. (D) Ton.32D/Flt3-Wt (Cont.) and Ton.32D/Flt3-Wt/c-Cbl-RQ/Cbl-b-CA (c-Cbl-RQ/Cbl-b-CA) cells, cultured in doxycycline-
containing medium, were cultured for 3 h with or without 5 mM LY294002 (LY), as indicated, in the absence of IL-3. Cells were further treated for 6 h
with 10 mM etoposide (VP16) or 1 mM doxorubicin (DXR), as indicated, and lysed. Cell lysates were analyzed by immunoblotting.
doi:10.1371/journal.pone.0027397.g003
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terminal to amino acids 758–776 directly or indirectly by activated
caspases under DNA damage stress when the kinase activity is
inactive.
Discussion
We have demonstrated in the present study that GSK3b should
play a crucial role in synergistic induction of apoptosis in
hematopoietic cells treated with DNA-damaging agents under
conditions where Jak2 is inhibited, because GSK3b inhibitors
prevented the apoptosis (Fig. 4A and data not shown). Under these
conditions, the PI3K/Akt pathway downstream of Jak2 is
downregulated, thus reducing the inhibitory phosphorylation of
GSK3b. According to previous reports, GSK3b is also activated
by etoposide or ceramide, which may be mediated indirectly
through PP2A activation [14,22,23]. In accordance with this,
etoposide or doxorubicin reduced the inhibitory phosphorylation
Figure 4. Synergistic induction of apoptosis in UT7/Jak2-V617F by etoposide and JakI-1 and effects of Boc-d-fmk on Jak2
downregulation. (A) UT7/Jak2-V617F cells were cultured for 12 h with 0.5 mM etoposide (VP16), 0.5 mM JakI-1, 25 mM LY294002, and 1 mM GSK3I-5,
as indicated in the absence of Epo, and analyzed for the cellular DNA content by flow cytometry. Percentages of apoptotic cells with sub-G1 DNA
content are indicated. (B) UT7/Jak2-V617F cells were cultured for 6 h with 5 mM etoposide (VP16), 1 mM JakI-1, and 100 mM Boc-d-fmk, as indicated, in
the absence of Epo and analyzed for the cellular DNA content. (C, D) 32D/EpoR cells deprived of Epo for 2 h were pretreated for 1 h with 100 mM Boc-
d-fmk (B-d-f), as indicated, or left untreated. Cells were then treated for 5 h with or without 5 mM etoposide (VP16) or 0.5 mM doxorubicin (DXR), as
indicated. Cells were lysed and analyzed by immunoblotting. (E) UT7/Jak2-V617F cells, cultured without Epo for 12 h, were treated with 1 mM JakI-1
and 100 mM Boc-d-fmk (B-d-f), as indicated, or left untreated. Cells were then treated with or without 5 mM etoposide (VP16), as indicated, for 6 h and
analyzed.
doi:10.1371/journal.pone.0027397.g004
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acid (Fig. 2C). Thus, it is speculated that, possibly through
activation of PP2A, DNA damage stress in combination with
inactivation of the PI3K/Akt pathway may activate GSK3b
beyond a threshold level where apoptosis is imminent. We have
previously implicated GSK3b activation in inhibition of Chk1-
mediated G2/M checkpoint activation leading to synergistic
induction of apoptosis in hematopoietic cells treated with
etoposide in the absence of Epo [10]. However, the synergistic
activation of Bax and caspase-3 by etoposide and JakI-1 in UT7/
Jak2-V617F was observed as early as 3 h after treatment (Fig. 5A),
thus suggesting that molecular mechanisms other than that
regulating cell cycle progression may also play an important role
in activation of apoptotic signaling downstream of GSK3b. In this
regard, GSK3b has been implicated in direct or indirect activation
of Bax, caspase-2, and caspase-3 leading to apoptosis [14,23,24].
These possibilities as well as the mechanisms involved in GSK3b
activation under DNA damage stress need to be addressed in
future studies.
The present study has implicated the ubiquitin proteasome
pathway in degradation of Jak2 under DNA stress, because the
proteasome inhibitor MG132 prevented the decline in Jak2
(Fig. 3A). Moreover, transient expression studies showed that Jak2
is polyubiquitinated when co-expressed with EpoR and autopho-
sphorylated on Y1007 (Fig. 3B). This is in agreement with the
previous report that Jak2 becomes polyubiquitinated when
autophosphorylated on Y1007 [19]. However, it also raises a
possibility that EpoR may play a role in polyubiquitination of Jak2
independent of its activation, which might explain the fact that
Jak2 was downregulated much more significantly in cells
expressing EpoR (Fig. 1D). Furthermore, the E3 ubiquitin ligases
c-Cbl and Cbl-b enhanced ubiquitination of Jak2-V617F in 293T
cells (Fig. 3C) and were implicated in degradation of Jak2 under
DNA damage stress in 32D cells, because overexpression of loss-
of-function mutants of both c-Cbl and Cbl-b impeded the
degradation (Fig. 3D). This may bear clinical relevance for
treatment of myeloproliferative neoplasms, because these mutants
of Cbls have been observed in these diseases [21]. It should be
noted, however, that in most cases the degradation of tyrosine
kinases through the ubiquitin proteasome system is triggered upon
its activation and autophosphorylation, which may create a
binding site for an E3 ligase [17]. In accordance with this, it was
reported that autophosphorylation of Jak2 on Y1007 creates a
binding site for the SOCS1 complex, resulting in ubiquitination
and proteasomal degradation of Jak2 [19]. It was more recently
reported that Jak2-V617F constitutively undergoes SOCS1- and
SOCS3-mediated polyubiquitination and proteasomal degrada-
tion [25]. In this report, JakI-1 was shown to inhibit the
degradation and to increase the expression level of Jak2-V617F.
In contrast with these reports, Jak2 is dephosphorylated on Y1007
when cells are deprived of Epo, and JakI-1 allowed DNA damage
to degrade Jak2-V617F in the present study. It should be also
noted that we could not detect significant polyubiquitination of
Jak2 or Jak2-V617F when they were downregulated in hemato-
poietic cells in response to DNA damage stress (negative data not
shown). Thus, the possibilities remain that MG132 and c-Cbl or
Cbl-b may affect the Jak2 downregulation through indirect
mechanisms, which needs to be addressed in future studies.
It has been reported that a Jak2 inhibitor, WP1066, induced
Jak2 degradation through a proteolytic mechanism that was not
inhibited by proteasome inhibitors [26,27]. A histone deacetylase
inhibitor, panobinostat, was also reported to downregulate the
Jak2-V617F expression, which was most likely through inhibition
of HSP90 by panobinostat [28]. A more recent report showed that
an HSP90 inhibitor, PU-H71, downregulated the expression of
Jak2 as well as Jak2-V617F and reduced viability of cells [29]. In
this report, it was found that HSP90 physically associated with
Jak2 or Jak2-V617F, which was independent of its phosphoryla-
tion status. Similarly with the present study, the downregulation
was inhibited by MG132. The authors thus concluded that HSP90
protects Jak2 and Jak2-V617F from proteasomal degradation,
although the possible involvement of caspases or other proteolytic
enzymes was not addressed. Therefore, it is possible that the
interaction with HSP90 may be involved in the downregulation of
Jak2 and Jak2-V617F in the present study. This possibility needs to
be addressed thoroughly in future studies. However, our
preliminary data suggest that Jak2 inhibition under DNA damage
stress dose not significantly affect its interaction with HSP90.
The tumor suppressor p53 plays a major role in DNA-damage
stress signaling to control cell cycle progression, DNA repair, and
apoptosis [30]. Intriguingly, Nakatake et al. [31] very recently
reported that Jak2-V617F inhibited the induction of p53
expression by DNA-damage stress. Unfortunately, we could not
examine the effects of Jak2-V617F expression and its inhibition on
DNA damage-induced expression of p53 in UT7 cells, because
these cells lack the normal TP53 transcript [32]. On the other
hand, as shown in Fig. 1B and 1C, the induction of p53 by
etoposide or doxorubicin was inhibited when Jak2 was inactivated
by Epo withdrawal in 32D/EpoR cells. This may be at least partly
due to the Epo-dependence of Chk1 activation in these cells [10],
which plays a role in induction of p53 [30]. Irrespective of the
mechanisms involved in modulation of the p53 induction by Jak2
or the V617F mutant, p53 may not play a significant role in DNA
damage-induced degradation of Jak2, which was observed
similarly in cells expressing p53 or not.
Recent studies have shown that caspase-mediated cleavage of
kinases can terminate prosurvival signaling or generate proapop-
totic peptide fragments that help to execute the death program
Figure 5. Caspase activation is involved in Jak2 degradation in cells under DNA damage stress. (A) UT7/Jak2-V617F cells, cultured
without Epo, were treated for 7 h with or without 1 mM JakI-1, as indicated, with 1 mM etoposide (VP16) added for indicated times before harvest.
Cells were then analyzed for activation of Bax or caspase-3 by flow cytometry. Percentages of cells with activated Bax or caspase-3 are plotted. FSC:
forward scatter. (B) UT7/Jak2-V617F cells, cultured without Epo, were pretreated for 1 h with 1 mM JakI-1, 100 mM Boc-d-fmk, or 1 mM GSK3I-5, as
indicated. Cells were further treated for 6 h with or without 5 mM VP16 and analyzed for loss of mitochondrial membrane potential and activation of
Bax or caspase-3, as indicated, by flow cytometry. (C) 32D/EpoR cells were deprived of Epo and pretreated with 100 mM Boc-d-fmk (B-d-f), as
indicated, or left untreated. Cells were then treated for 5 h with or without etoposide (VP16), as indicated, before harvest. Immunoprecipitates
obtained using anti-Jak2 (06–255) were analyzed by immunoblotting using anti-Jak2 (M-126) and anti-Jak2 (C-20), as indicated. The numbers of cells
treated with etoposide were 2.5 times that of cells untreated. An arrow indicates the 100-kDa band. (D) UT7/Jak2-V617F cells, cultured without Epo,
were pretreated for 1 h with or without 1 mM JakI-1, as indicated. Cells were then treated for 8 h with or without 5 mM etoposide (VP16), as indicated,
before harvest. Immunoprecipitates obtained using anti-Jak2 (06–255) were analyzed by immunoblotting using indicated antibodies. The number of
cells treated with etoposide was 2 times that of cells untreated. (E) UT7/Jak2-V617F cells, cultured without Epo, were pretreated for 1 h with 1 mM
JakI-1 and 20 mM Boc-d-fmk (B-d-f), as indicated. Cells were then treated for 6 h with or without 5 mM etoposide (VP16), as indicated, before harvest.
Immunoprecipitates obtained using anti-Flag was were analyzed by immunoblotting using anti-Jak2 (06–255). The numbers of cells treated with
etoposide were 2.5 times that of cells untreated.
doi:10.1371/journal.pone.0027397.g005
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the apoptotic process, it is tempting to speculate that this cleavage
may play an important role in the synergistic induction of
apoptosis under DNA damage stress. Judging from the size of
putative cleavage product (100 kDa), which reacts with anti-Jak2
(06–255) against the Jak2 amino acids 758–776, the cleavage site
should be located within the tyrosine kinase (JH1) domain or
between the JH1 and the pseudokinase (JH2) domains, the latter of
which possesses the inhibitory effect on the kinase activity [1].
Thus, caspases may abolish the Jak2 kinase activity by cleaving it
within the JH1 domain to terminate prosurvival signaling.
Alternatively, it is also possible that the cleavage between the
JH1 and JH2 domains create an active tyrosine kinase domain
fragment that may play a proapoptotic or possibly prosurvival role,
although we could not detect the smaller C-terminal fragment of
Jak2 using anti-Jak2 (C-20). We are currently trying to identify the
cleavage site by mutagenesis of the putative caspase cleavage sites
and to determine the significance of Jak2 and Jak2-V617F
cleavage on the synergistic induction of apoptosis.
Although several Jak2 inhibitors have been developed and
under clinical evaluation, the therapy of patients with myelopro-
liferative neoplasms with these agents has thus far shown only
modest effects at best [11]. In this regard, the present study may
contribute to the development of possible combination therapies of
Jak2 inhibitors and DNA-damaging chemotherapeutic agents.
Materials and Methods
Cells and reagents
A murine IL-3-dependent cell line, 32Dcl3, and a clone of
32Dcl3 expressing the Epo receptor, 32D/EpoR, have been
previously described [13] and maintained in RPMI1640 medium
supplemented with 10% FCS and 10% WEHI conditioning
medium as the source of IL-3 or 1 U/ml human recombinant
Epo. Ton.32D (A clone of 32Dcl3 cells transfected with pTet-On
(Clontech)), Ton.32D/Flt3-Wt (Ton.32D cells expressing Flt3),
and Ton.32D/Flt3-Wt/c-Cbl-RQ/Cbl-b-CA (Flt3-expressing
Ton.32D cells that overexpress loss-of-function mutants of both
c-Cbl (c-Cbl-R420Q) and Cbl-b (Cbl-b-C373A) when cultured
with doxycycline) have also been described (Oshikawa, G., Nagao,
T., Wu, N., Kurosu, T., and Miura, O., submitted for
publication). A human leukemic cell line expressing the endoge-
nous EpoR, UT7 [12], was kindly provided by Dr N. Komatsu
and maintained in RPMI1640 medium with 10% FCS and 1 U/
ml Epo. PLAT-A [34], an amphotropic virus packaging cell line,
and 293T, a human embryonic kidney cell line, were kindly
provided by Dr. T. Kitamura and Dr. S. Yamaoka, respectively,
and maintained in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% FCS.
Recombinant human Epo was kindly provided by Chugai
Pharmaceutical Co. Ltd. (Tokyo, Japan). Doxycycline was
purchased from Sigma (St Louis, MO, USA). Etoposide,
doxorubicin, hygromycin, and LiCl were purchased from Wako
(Tokyo, Japan). The PI3K inhibitor LY294002, the MEK1
inhibitor PD98059, the GSK3b inhibitor SB216763, MG132,
JakI-1, AG490, and okadaic acid were purchased from Calbio-
chem (La Jolla, CA, USA). GSK3b-inhibitor #5 (GSK3I-5) [35]
was synthesized and kindly provided by Dr. H. Kagechika. The
pan-caspase inhibitor Boc-d-fmk was purchased from Biovision
(Mountain View, CA, USA). DiOC6 was purchased from
Invitrogen (Carlsbad, CA, USA).
Rabbit polyclonal antibodies against Akt, cleaved caspase-3,
GSK3b, p85, phospho-Jak2-Y1007/1008, phospho-GSK3a/b-
S9/21, and p85 as well as rabbit or mouse monoclonal antibody
against phospho-STAT5-Y694 or p53 (1C12), respectively, were
purchased from Cell Signaling Technology (Beverly, MA, USA).
Rabbit polyclonal antibodies against c-Cbl, Cbl-b, EpoR, Jak2 (C-
20 and M-126), and STAT5A as well as a mouse monoclonal
antibody against a-tubulin were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). A rabbit antibody against
Jak2 (06–255) and a mouse monoclonal antibody against
phosphotyrosine (4G10) were purchased from Millipore (Billerica,
MA, USA). Anti-Jak2 (06–255) was used throughout the present
studies unless described otherwise. A mouse monoclonal antibody
against FLAG (M2) and b-actin were purchased from Sigma. A
mouse monoclonal antibody against polyubiquitin (FK-1) was
purchased from Enzolifesciences (Farmingdale, NY, USA). A
mouse monoclonal antibody against Bax (YTF-6A7) was pur-
chased from Trevigen (Gaithersburg, MD, USA).
Expression plasmids
An expression plasmid for Jak2-V617F, pMSCV-Jak2V617F
[36], was kindly provided by Dr. R. Skoda. Expression plasmids,
tTA-IRES-GFP (Addgene plasmid 18783) and pRK5-Ubiquitin-
WT (Addgene plasmid 17608) [37], were purchased from
Addgene (Cambridge, MA, USA). An Expression plasmid for
murine EpoR, pXM-EpoR-Wt, was described previously [13].
Expression plasmids encoding wild-type Jak2 (pRK5-Jak2-Wt) and
a kinase negative mutant Jak2 (pRK5-Jak2-KE) [38] were kindly
provided by Dr. JN. Ihle. An expression plasmid, pMX-puro-
STAT5A1*6 [15], was kindly provided by Dr. T. Kitamura. An
expression plasmid, pUSE-myr-Akt1, was purchased from Milli-
pore. pRevTRE-c-Cbl and pRevTRE-Cbl-b have been described
[39]. pRevTRE and pTet-On were purchased from Clontech
(Mountain View, CA, USA).
To prepare a Flag-tagged Jak2-V617F expression vector, the
XhoI/HpaI fragment of pMSCV-Jak2V617F was subcloned into
the pGEM-T-easy vector, purchased from Promega (Madison,
WI, USA), thus adding the FLAG-tag coding sequence at the 5’-
terminus, to give pGEM-T-easy-Jak2V617F. The SalI/SphI
fragment of pGEM-T-easy-Jak2V617F was subsequently sub-
cloned between the SalI/SphI site in the pRevTRE vector to give
pRevTRE-Jak2V617F. A retroviral expression plasmid, pRev-
TRE-myr-Akt1, was constructed by subcloning the HindIII/PmeI
fragment from pUSE-myr-Akt1 into the HindIII/HpaI site of
pRevTRE.
Transfection and infection
For retroviral infection, PLAT-A cells were first transfected with
tTA-IRES-GFP using the Lipofectamin reagent (GIBCO-BRL,
Grand Island, NY), according to the manufacturer’s instruction.
The recombinant retrovirus was harvested 48 h after transfection
and used to infect UT7 cells. Cells expressing green fluorescent
protein (GFP) were sorted using a Becton Dickinson FACSscan
flow cytometer (Mountain View, CA, USA). Isolated cells were
infected again with the pRevTRE-Flag-Jak2V617F or pRevTRE
retrovirus and selected in medium containing 600 mg/ml hygro-
mycin. Pools of infected cells were used in subsequent experiments
as UT7/Jak2-V617F or UT7/RevTRE cells. Ton.32D cells were
similarly infected with the pRevTRE-myr-Akt1 or pRevTRE
retrovirus and selected in medium containing 600 mg/ml of
hygromycin to be used as 32D/Akt-myr or 32D/RevTRE cells,
respectively. 32D/EpoR cells were infected with the pMX-puro or
pMX-puro-STAT5A1*6 retrovirus and selected in medium
containing 1 mg/ml puromycin to be used as 32DE/pMX or
32DE/STAT5A1*6 cells, respectively.
For transient expression in 293T cells, cells were transfected
with indicated plasmids using the Lipofectamine reagent. Cells
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tion and immunoblotting.
Immunoprecipitation and immunoblot analyses
For immunoprecipitation experiments, cells were lysed in a lysis
buffer containing 1% Triton X-100, 20 mM Tris-HCl (pH 7.5),
150 mM NaCl, 1 mM EDTA, 1 mM sodium orthovanadate,
1 mM phenylmethylsulfonyl fluoride and 10 mg/ml each of
aprotinin and leupeptin. Cell lysates were subjected to immuno-
precipitation and immunoblotting as described previously [13].
For immunoblot analysis of total cell lysates, samples were
prepared by mixing an aliquot of cell lysates with an equal
volume of 2X Laemmli’s sample buffer and heating at 100uC for
5 min. The results shown are representative of experiments
repeated at least three times.
Flow cytometric analyses of apoptosis, Bax, caspase-3,
and mitochondrial membrane potential
Flow cytometric analysis of cell cycle and apoptosis was
performed as described previously [40]. Flow cytometric analyses
of the Bax conformational change and caspase-3 cleavage were
performed using specific antibodies against activated Bax and
cleaved caspase-3 as described previously [41]. For analysis of
mitochondrial membrane potential, cells were stained with a
lipophilic cation (5, 5’, 6, 6’, tetrachloro-1, 1’, 3, 3’-tetraethylben-
zimidazolyl carbocyanin iodide) using the DePsipher kit (Trevigen)
and analyzed by flow cytometry as described previously [42].
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